Skip to NavigationSkip to content

AstraZeneca seals manufacturing deal to deliver COVID-19 vaccine in China

Published on 07/08/20 at 10:15am

AstraZeneca has signed its first deal in China to produce and deliver its vaccine candidate against COVID-19 in the country, partnering up with manufacturing firm Shenzhen Kangtai Biological Products.

The deal is for 100 million doses of the candidate by the end of this year, known as AZD1222, which AZ is working on in partnership with the University of Oxford.

The partnership stipulates that Shenzhen Kangtai must raise its capacity to deliver 200 million by the close of 2021. There are around 1.4 billion citizens in China, and the country is AstraZeneca’s biggest market.

Early data has shown that the candidate has successfully generated immune and T cell responses in patients, and Phase 2/3 trials kicking off back in May. The agreement also leaves the door open for collaboration between the two firms on the delivery of the vaccine to other global markets.

The deal is the latest in a series recently signed by the pharma giant, which includes the promise of 400 million doses to Europe, with the goal of ramping up capacity to deliver one billion  doses by September this year.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches